They took liraglutide 3.0 mg or 1.8 mg, the Victoza dose for diabetes, or placebo, once a day for 56 weeks. Weight fell by 6.0% on 3.0 mg, 4.7% on 1.8 mg and 2.0% on placebo. It was published in JAMA in 2015.1
How the trial was run
The trial ran at 126 sites in 9 countries between June 2011 and January 2013. Of 1,361 people assessed, 846 were assigned in a 2:1:1 ratio to liraglutide 3.0 mg, liraglutide 1.8 mg or placebo, injected once a day. Participants were 18 or older and took no more than three oral diabetes medicines, metformin, a thiazolidinedione or a sulfonylurea, and had a stable weight. After the 56 weeks of treatment, there was a 12-week follow-up period off the drug, during which participants were observed without treatment.1
What it found
- From average starting weights of about 106 kg, weight fell by 6.0%, or 6.4 kg, on 3.0 mg; 4.7%, or 5.0 kg, on 1.8 mg; and 2.0%, or 2.2 kg, on placebo.
- A loss of at least 5% was reached by 54.3%, 40.4% and 21.4%.
- A loss of more than 10% was reached by 25.2%, 15.9% and 6.7%.
Davies et al., 2015.1
No pancreatitis was reported in the trial. The authors concluded that daily liraglutide 3.0 mg led to weight loss over 56 weeks in adults with type 2 diabetes and excess weight, and that longer studies were needed for efficacy and safety. The trial is registered as NCT01272232.1
The Saxenda label includes this trial as its Study 2 and, with its own counting method, reports a loss of 5.4% on 3.0 mg against 1.7% on placebo, from a starting weight of about 106 kg.2 Both describe the same people; the difference comes from how missing data were handled.
3.0 mg against 1.8 mg
The trial tested the diabetes dose and the weight dose side by side. The higher dose lowered weight more, 6.0% against 4.7%, and raised the share losing more than 10% from 15.9% to 25.2%. It also brought more stomach and gut complaints than the lower dose.1 That gap is the reason Saxenda uses 3.0 mg, while Victoza for blood sugar stops at 1.8 mg.2,3
Why the loss is smaller with diabetes
In the Saxenda trial in adults without diabetes, the same 3.0 mg dose lowered weight by 7.4% against 3.0% on placebo.2 The same pattern holds for the newer medicines: semaglutide 2.4 mg lowered weight by 14.9% without diabetes and 9.6% with it, and tirzepatide 15 mg by 20.9% and 14.7%.4,5 People with type 2 diabetes tend to lose less on every GLP-1 medicine tested so far in these trials.
Side effects
On Saxenda across its trials, nausea was reported by 39.3% against 13.8% on placebo, diarrhea by 20.9% against 9.9% and vomiting by 15.7% against 3.9%. In people with diabetes, low blood sugar is a particular risk when liraglutide is combined with a sulfonylurea.2 Our page on nausea on a GLP-1 covers what helps.
Limits
Liraglutide 3.0 mg has since been overtaken for weight by the weekly medicines, whose own trials found much larger losses. SCALE Diabetes remains the reference for liraglutide in people with diabetes, a group that the newer trials, such as STEP 2 and SURMOUNT-2, also studied separately.4,5
Sources
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA 2015;314:687-699. doi:10.1001/jama.2015.9676
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; sections 2, 5, 6.1 and 14. dailymed.nlm.nih.gov
- VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; section 2. dailymed.nlm.nih.gov
- Davies M, F忙rch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984; and Wilding JPH, et al. STEP 1. N Engl J Med 2021;384:989-1002. doi:10.1016/S0140-6736(21)00213-0
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov
Related analyses
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic vs Wegovy: the same drug under two labels, compared by dose, results and price
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Wegovy weight loss chart: the trial results week by week, in your own weight
Log your weight and HbA1c and see both trends on one screen.
Open Dose Insider